

REMARKSAmendment of the specification

Paragraphs beginning at line 25 on page 10, line 18 on page 11, line 27 on page 15, and the abstract of the present application have been amended to correct an obvious typographical error in the stereochemistry at the methyl group at C-34 (see the numbering of rapamycin on page 2). The stereochemistry of the C-34 methyl group of all the above tetrazole-containing rapamycin analogs should be (R) (bold bond) rather than (S) (dashed bond). The compounds are derivatives of rapamycin, whose structure is correctly described and presented in the specification. An ordinary artisan would recognize that the C-34 methyl group has the (R) stereochemistry based on the fact that the synthesis of all the above tetrazole-containing rapamycin analogs uses rapamycin as the starting material – see Examples 1 and 2 on pages 18 and 19, and the description of the synthesis of the compounds on page 16, line 6 to page 18, line 5. Also, the correct stereochemistry of rapamycin is depicted on page 2. Because the amendment to the specification does not introduce new matter, entry thereof by the PTO is respectfully requested.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to the **Squire, Sanders and Dempsey Deposit Account No. 07-1850.**

Respectfully submitted,

Date:

October 15 2008
Squire, Sanders & Dempsey L.L.P.
One Maritime Plaza
Suite 300
San Francisco, CA 94111
Facsimile (415) 393-9887
Telephone (415) 954-0397 (direct)
Telephone (415) 954-0200

Gloria M. Gusler
Gloria M. Gusler, Ph.D.
Attorney for Applicants
Reg. No. 50,282